The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on February 13.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to a statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
By Joseph Maliakan Three terrible things that were inflicted especially on the poor and marginalized people…
Mr. Sajith Kumar P K : Along with Mr. Sajith Kumar, four other prominent leaders…
Sajith Kumar P.K : The Budget is touched to the Structural Reforms especially in Maritime…
By Joseph Maliakan The Institute of Liver and Biliary Sciences (ILBS) is a mono-super specialty…
By Joseph Maliakan In a judgment that will have far-reaching consequences for the protection of…
By Joseph Maliakan Education according to the Indian Constitution, is in the concurrent list and…
This website uses cookies.